Antibody Response After SARS-CoV-2 Infection and Implications for Immunity A Rapid Living Review

被引:72
|
作者
Arkhipova-Jenkins, Irina [1 ,2 ,5 ]
Helfand, Mark [2 ,3 ,6 ]
Armstrong, Charlotte [1 ,2 ]
Gean, Emily [1 ,2 ]
Anderson, Joanna [2 ,4 ]
Paynter, Robin A. [1 ,2 ]
Mackey, Katherine [2 ,4 ,6 ]
机构
[1] Portland VA Res Fdn, Sci Resource Ctr, AHRQ Evidence Based Practice Ctr Program, Portland, OR USA
[2] VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,Mail Code R&D 71, Portland, OR 97239 USA
[3] Portland VA Res Fdn, Sci Resource Ctr, AHRQ Evidence Based Practice Ctr Program, VA Evidence Synth Program, Portland, OR USA
[4] VA Evidence Synth Program, Portland, OR USA
[5] Portland VA Res Fdn, 3710 SW US Vet Hosp Rd,Bldg 106,R212, Portland, OR 97239 USA
[6] VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,Mail Code P3MED, Portland, OR 97239 USA
关键词
COVID-19; IGG;
D O I
10.7326/M20-7547
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The clinical significance of the antibody response after SARS-CoV-2 infection remains unclear. Purpose: To synthesize evidence on the prevalence, levels, and durability of detectable antibodies after SARS-CoV-2 infection and whether antibodies to SARS-CoV-2 confer natural immunity. Data Sources: MEDLINE (Ovid), Embase, CINAHL, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, World Health Organization global literature database, and Covid19 reviews.org from 1 January through 15 December 2020, limited to peer-reviewed publications available in English. Study Selection: Primary studies characterizing the prevalence, levels, and duration of antibodies in adults with SARS-CoV-2 infection confirmed by reverse transcriptase polymerase chain reaction (RT-PCR); reinfection incidence; and unintended consequences of antibody testing. Data Extraction: Two investigators sequentially extracted study data and rated quality. Data Synthesis: Moderate-strength evidence suggests that most adults develop detectable levels of IgM and IgG antibodies after infection with SARS-CoV-2 and that IgG levels peak approximately 25 days after symptom onset and may remain detectable for at least 120 days. Moderate-strength evidence suggests that IgM levels peak at approximately 20 days and then decline. Low-strength evidence suggests that most adults generate neutralizing antibodies, which may persist for several months like IgG. Low-strength evidence also suggests that older age, greater disease severity, and presence of symptoms may be associated with higher antibody levels. Some adults do not develop antibodies after SARS-CoV-2 infection for reasons that are unclear. Limitations: Most studies were small and had methodological limitations; studies used immunoassays of variable accuracy. Conclusion: Most adults with SARS-CoV-2 infection confirmed by RT-PCR develop antibodies. Levels of IgM peak early in the disease course and then decline, whereas IgG peaks later and may remain detectable for at least 120 days.
引用
收藏
页码:811 / +
页数:12
相关论文
共 50 条
  • [1] Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection
    Helfand, Mark
    Fiordalisi, Celia
    Wiedrick, Jack
    Ramsey, Katrina L.
    Armstrong, Charlotte
    Gean, Emily
    Winchell, Kara
    Arkhipova-Jenkins, Irina
    [J]. ANNALS OF INTERNAL MEDICINE, 2022, 175 (04) : 547 - +
  • [2] Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection-Final Update of a Living, Rapid Review
    Holmer, Haley K.
    Mackey, Katherine
    Fiordalisi, Celia, V
    Helfand, Mark
    [J]. ANNALS OF INTERNAL MEDICINE, 2023, 176 (01) : 85 - +
  • [3] The Antibody Response to SARS-CoV-2 Infection
    Hueston, Linda
    Kok, Jen
    Guibone, Ayla
    McDonald, Damien
    Hone, George
    Goodwin, James
    Carter, Ian
    Basile, Kerri
    Sandaradura, Indy
    Maddocks, Susan
    Sintchenko, Vitali
    Gilroy, Nicole
    Chen, Sharon
    Dwyer, Dominic E.
    O'Sullivan, Matthew V. N.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (09):
  • [4] SARS-CoV-2 Immunity: Review of Immune Response to Infection and Vaccination
    Ahmad, Rahnuma
    [J]. BANGLADESH JOURNAL OF MEDICAL SCIENCE, 2021, 20 : S32 - S40
  • [5] Antibody response to SARS-CoV-2 infection in humans: A systematic review
    Post, Nathan
    Eddy, Danielle
    Huntley, Catherine
    van Schalkwyk, May C. I.
    Shrotri, Madhumita
    Leeman, David
    Rigby, Samuel
    Williams, Sarah V.
    Bermingham, William H.
    Kellam, Paul
    Maher, John
    Shields, Adrian M.
    Amirthalingam, Gayatri
    Peacock, Sharon J.
    Ismail, Sharif A.
    [J]. PLOS ONE, 2020, 15 (12):
  • [6] Antibody response three months after SARS-CoV-2 infection
    Oktay Gultekin, Efdal
    Gultekin, Onur
    Coskun, Arzu
    Aksak, Tiince
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (10) : 4712 - 4718
  • [7] Persistence of the neutralizing antibody response after SARS-CoV-2 infection
    Shim, Sang-Mu
    Kim, Jun-Won
    Jung, Sunhee
    Jung, Yujung
    Woo, Hye-Min
    Yang, Jeong-Sun
    Kim, Kyung-Chang
    Lee, Joo-Yeon
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (04) : 614.e1 - 614.e4
  • [8] Immunoglobulin A response to SARS-CoV-2 infection and immunity
    Esmat, Khaleqsefat
    Jamil, Baban
    Kheder, Ramiar Kaml
    Kombe, Arnaud John Kombe
    Zeng, Weihong
    Ma, Huan
    Jin, Tengchuan
    [J]. HELIYON, 2024, 10 (01)
  • [9] Innate immunity to SARS-CoV-2 infection: a review
    Abrahao Silva, Marcos Jesse
    Rodrigues, Yan Correa
    Batista Lima, Karla Valeria
    Gondim Costa Lima, Luana Nepomuceno
    [J]. EPIDEMIOLOGY AND INFECTION, 2022, 150
  • [10] The early antibody response to SARS-Cov-2 infection
    Dittadi, Ruggero
    Afshar, Haleh
    Carraro, Paolo
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2020, 58 (10) : E201 - E203